L-MTO-PE - a potential drug for cancer therapy
Languages of publication
Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a syntetic lipophilic analogue of muramyl dipeptide, stimulates monocytes/macrophages to kill a variety of tumor cells in vitro and in vivo. Encapsulation of MTP-PE into multilamellar liposomes (L-MTP-PE) was specifically designed for in vivo targeting to macrophages by i.v. infusion and is the only form of the drug currently available for clinical trials (CGP 19835A Lipid). L-MTP-PE is presently undergoing clinical trials in patients with recurrent osteosarcoma and melanoma. L-MTP-PE combined with other anticancer agents may thus improve long-term cure rates of patients with this diseases.
Publication order reference
K.Dzierzbicka, ul. Przyjemna 2c/11, 80-054 Gdansk, Poland